Detection of Alzheimer's disease at mild cognitive impairment and disease progression using autoantibodies as blood‐based biomarkers

Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring - Tập 3 - Trang 51-62 - 2016
Cassandra A. DeMarshall1,2,3, Eric P. Nagele1,4, Abhirup Sarkar1,2,3, Nimish K. Acharya1,3, George Godsey2,3, Eric L. Goldwaser1,2,3, Mary Kosciuk1,3, Umashanger Thayasivam5, Min Han1,2,3, Benjamin Belinka4, Robert G. Nagele1,3,4
1Biomarker Discovery Center, New Jersey Institute for Successful Aging, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA
2Graduate School of Biomedical Sciences, Rowan University, Stratford, NJ, USA
3Department of Geriatrics and Gerontology, Rowan University School of Osteopathic Medicine, Stratford, NJ, USA
4Durin Technologies, Inc., New Brunswick, NJ, USA
5Department of Mathematics, Rowan University, Glassboro, NJ, USA

Tóm tắt

AbstractIntroductionThere is an urgent need to identify biomarkers that can accurately detect and diagnose Alzheimer's disease (AD). Autoantibodies are abundant and ubiquitous in human sera and have been previously demonstrated as disease‐specific biomarkers capable of accurately diagnosing mild‐moderate stages of AD and Parkinson's disease.MethodsSera from 236 subjects, including 50 mild cognitive impairment (MCI) subjects with confirmed low CSF Aβ42 levels, were screened with human protein microarrays to identify potential biomarkers for MCI. Autoantibody biomarker performance was evaluated using Random Forest and Receiver Operating Characteristic curves.ResultsAutoantibody biomarkers can differentiate MCI patients from age‐matched and gender‐matched controls with an overall accuracy, sensitivity, and specificity of 100.0%. They were also capable of differentiating MCI patients from those with mild‐moderate AD and other neurologic and non‐neurologic controls with high accuracy.DiscussionAutoantibodies can be used as noninvasive and effective blood‐based biomarkers for early diagnosis and staging of AD.

Tài liệu tham khảo

10.1016/j.jalz.2015.02.003 10.1016/j.pneurobio.2011.07.004 10.1016/S0140-6736(06)69113-7 Casey D.A., 2010, Drugs for Alzheimer's disease: are they effective?, P T, 35, 208 10.1016/S0197-4580(97)00056-0 10.1073/pnas.191044198 10.1097/00005072-199812000-00009 10.1212/WNL.46.3.707 10.1002/1531-8249(199903)45:3<358::AID-ANA12>3.0.CO;2-X 10.2174/156720509788929237 10.1016/j.jalz.2014.02.004 10.1212/01.wnl.0000345014.48839.71 10.1001/archneur.56.3.303 10.1016/j.jalz.2011.03.008 10.1016/j.jalz.2013.01.013 10.1016/j.jalz.2010.06.004 10.1038/nrneurol.2010.4 10.1212/WNL.52.8.1555 10.1001/archneur.59.11.1729 10.1016/S1474-4422(06)70355-6 10.1001/jama.2009.1064 10.3233/JAD-2009-1177 10.1016/j.jalz.2007.08.006 10.1111/j.1749-6632.2009.04944.x 10.1373/clinchem.2013.202937 Morris G.P., 2014, Inconsistencies and controversies surrounding the amyloid hypothesis of Alzheimer's disease, Acta Neuropathol Commun, 2, 135 10.1371/journal.pone.0028092 10.1016/j.jalz.2014.08.099 10.1016/j.jalz.2013.09.016 10.1038/nm.3466 10.3233/JAD-130380 10.3389/fgene.2013.00150 10.1371/journal.pone.0060726 10.1016/j.cell.2010.11.054 10.1371/journal.pone.0023112 10.1371/journal.pone.0032383 10.1016/j.imlet.2015.09.010 10.1016/j.jalz.2010.03.008 10.1002/ana.21610 10.1016/j.jalz.2013.12.023 10.1002/ana.410070516 Sheikh J.I., 1986, Clinical Gerontology: A Guide to Assessment and Intervention, 165 10.1016/0022-3956(75)90026-6 10.1212/WNL.43.11.2412-a 10.1016/j.jalz.2013.05.1769 10.1159/000345605 10.1023/A:1010933404324 10.1159/000330750 10.2217/bmm.12.48 10.1007/s00702-012-0772-4 10.1002/ana.22405 10.1016/bs.irn.2015.05.005
Thông tin
Thông tin xuất bản

Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring

Tập 3

51-62

Thông tin tác giả